In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 126 to 150 of 392

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]	Technology appraisal guidance	4 June 2025
Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338	Technology appraisal guidance	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]	Technology appraisal guidance	27 November 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Technology appraisal guidance	26 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]	Technology appraisal guidance	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)	NICE guideline	26 March 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment	NICE guideline	6 August 2025
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	21 May 2025
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]	Highly specialised technology	29 January 2025
Fruquintinib for previously treated metastatic colorectal cancer ID6274	Technology appraisal guidance	5 March 2025
Gambling-related harms: identification, assessment and management	NICE guideline	TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]	Technology appraisal guidance	TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]	Technology appraisal guidance	25 June 2025
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glaucoma - lerdelimumab (CAT-152) [ID383]	Technology appraisal guidance	TBC

Results per page

10
25
50
All